

Table S11. Important factors in treatment. (For patients diagnosed on MRI)

	Pain vs disability		Rapid vs stable treatment effect		Treatment effect vs safety	
	pain	disability	Rapid effects	Stable effect	Treatment effect	safety
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Total (N=317)	146 (46.1%)	171 (53.9%)	59 (18.6%)	258 (81.4%)	137 (43.2%)	180 (56.8%)
Sex						
Male (n=172)	70 (40.7%)	102 (59.3%)	29 (16.9%)	143 (83.1%)	81 (47.1%)	91 (52.9%)
Female (n=145)	76 (52.4%)	69 (47.6%)	30 (20.7%)	115 (79.3%)	56 (38.6%)	89 (61.4%)
<i>P</i> -value		0.049		0.467		0.161
Age group, years						
19-29 (n=57)	29 (50.9%)	28 (49.1%)	10 (17.5%)	47 (82.5%)	24 (42.1%)	33 (57.9%)
30-39 (n=59)	24 (40.7%)	35 (59.3%)	10 (16.9%)	49 (83.1%)	24 (40.7%)	35 (59.3%)
40-49 (n=68)	31 (45.6%)	37 (54.4%)	16 (23.5%)	52 (76.5%)	26 (38.2%)	42 (61.8%)
50-59 (n=70)	28 (40.0%)	42 (60.0%)	12 (17.1%)	58 (82.9%)	36 (51.4%)	34 (48.6%)
≥60 (n=63)	34 (54.0%)	29 (46.0%)	11 (17.5%)	52 (82.5%)	27 (42.9%)	36 (57.1%)
<i>P</i> -value		0.427		0.846		0.592
Symptom onset time						
<4 weeks (n=31)	16 (51.6%)	15 (48.4%)	5 (16.1%)	26 (83.9%)	20 (64.5%)	11 (35.5%)
≥4 weeks to <12 weeks (n=66)	33 (50.0%)	33 (50.0%)	18 (27.3%)	48 (72.7%)	28 (42.4%)	38 (57.6%)
≥12 weeks to <12 months (n=58)	18 (31.0%)	40 (69.0%)	14 (24.1%)	44 (75.9%)	25 (43.1%)	33 (56.9%)
≥12 months (n=162)	79 (48.8%)	83 (51.2%)	22 (13.6%)	140 (86.4%)	64 (39.5%)	98 (60.5%)
<i>P</i> -value		0.009		0.064		0.084
Severity						
Severe (n=113)	48 (42.5%)	65 (57.5%)	20 (17.7%)	93 (82.3%)	55 (48.7%)	58 (51.3%)
Moderate to severe (n=105)	53 (50.5%)	52 (49.5%)	21 (20.0%)	84 (80.0%)	39 (37.1%)	66 (62.9%)
Mild to moderate (n=99)	45 (45.5%)	54 (54.5%)	18 (18.2%)	81 (81.8%)	43 (43.4%)	56 (56.6%)
<i>P</i> -value		0.491		0.901		0.229